UBX Tiesioginiai signalai | Didinkite pelną su Getagraph.com

Live Chart Being Loaded With Signals

Commentary (29 bal. 2024 @ 20:24):

Unity Biotechnology, Inc., a biotechnology company, engages in the research and development of therapeutics to slow, halt, or reverse diseases of aging...

Stats
Šios dienos apimtis	28 773.00
Vidutinė apimtis	90 258.00
Rinkos kapitalizacija	25.43M
EPS	$0 ( 2024-04-03 )
Kita pelno data	( $-0.570 ) 2024-05-14
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.560
ATR14	$0.00500 (0.33%)

Insider Trading

Date	Person	Action	Amount	type
2024-03-26	Nguyen Alexander Hieu	Buy	30 000	Stock Option (Right to Buy)
2024-03-26	Nguyen Alexander Hieu	Buy	20 000	Common Stock, $0.0001 par value
2024-02-02	Ghosh Anirvan	Sell	680	Common Stock, $0.0001 par value
2024-01-30	Ghosh Anirvan	Sell	1 183	Common Stock, $0.0001 par value
2023-11-02	Ghosh Anirvan	Sell	589	Common Stock, $0.0001 par value

INSIDER POWER
55.05
Last 99 transactions
Buy: 2 792 498 \| Sell: 401 244

Tūris Koreliacija

Ilgas: 0.03 (neutral)

Trumpas: 0.11 (neutral)

Signal:(48.953) Neutral

UNITY Biotechnology Inc Koreliacija

10 Labiausiai teigiamai susiję koreliacijos
XLRN	0.938
BRACU	0.938
NVCN	0.934
LX	0.931
ATRS	0.924
SY	0.924
ATCX	0.923
PUCK	0.919
GXII	0.919
OVID	0.918

10 Labiausiai neigiamai susiję koreliacijos
NAKD	-0.928
AHPI	-0.923
AMGN	-0.908
PROC	-0.906
GRPH	-0.905
GRIN	-0.903
LCAP	-0.899
LAWS	-0.896
TRIT	-0.892
CYTO	-0.888

Ar žinojote?

Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).

Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.

UNITY Biotechnology Inc Koreliacija - Valiuta/Žaliavos

0.75
( moderate )

0.79
( moderate )

0.00
( neutral )

-0.75
( moderate negative )

-0.73
( moderate negative )

UNITY Biotechnology Inc Finansinės ataskaitos

Annual	2023
Pajamos:	$0
Bruto pelnas:	$-1.18M (0.00 %)
EPS:	$-2.70

FY	2023
Pajamos:	$0
Bruto pelnas:	$-1.18M (0.00 %)
EPS:	$-2.70

FY	2022
Pajamos:	$236 000
Bruto pelnas:	$-1.94M (-823.73 %)
EPS:	$-6.08

FY	2021
Pajamos:	$4 784.00
Bruto pelnas:	$0.00 (0.00 %)
EPS:	$-0.0109

Financial Reports:

No articles found.

UNITY Biotechnology Inc

Unity Biotechnology, Inc., a biotechnology company, engages in the research and development of therapeutics to slow, halt, or reverse diseases of aging. The company's lead drug candidate includes UBX1325, which is Phase II clinical trial for the treatment of age-related diseases of the eye, including diabetic macular edema, age-related macular degeneration, and diabetic retinopathy. It also develops UBX1967 for the treatment of ophthalmologic diseases; UBX2050, a human anti-Tie2 agonist monoclonal antibody for the treatment of age-related eye diseases; and UBX2089, a a-Klotho hormone drug candidate for multiple neurology indications. The company was formerly known as Forge, Inc. and changed its name to Unity Biotechnology, Inc. in January 2015. Unity Biotechnology, Inc. was incorporated in 2009 and is headquartered in South San Francisco, California.